JP2014526559A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526559A5
JP2014526559A5 JP2014531996A JP2014531996A JP2014526559A5 JP 2014526559 A5 JP2014526559 A5 JP 2014526559A5 JP 2014531996 A JP2014531996 A JP 2014531996A JP 2014531996 A JP2014531996 A JP 2014531996A JP 2014526559 A5 JP2014526559 A5 JP 2014526559A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
mab
efficacy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014531996A
Other languages
English (en)
Japanese (ja)
Other versions
JP6204915B2 (ja
JP2014526559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/056492 external-priority patent/WO2013043973A2/en
Publication of JP2014526559A publication Critical patent/JP2014526559A/ja
Publication of JP2014526559A5 publication Critical patent/JP2014526559A5/ja
Application granted granted Critical
Publication of JP6204915B2 publication Critical patent/JP6204915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014531996A 2011-09-23 2012-09-21 悪液質治療 Active JP6204915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538309P 2011-09-23 2011-09-23
US61/538,309 2011-09-23
PCT/US2012/056492 WO2013043973A2 (en) 2011-09-23 2012-09-21 Cachexia treatment

Publications (3)

Publication Number Publication Date
JP2014526559A JP2014526559A (ja) 2014-10-06
JP2014526559A5 true JP2014526559A5 (OSRAM) 2015-10-29
JP6204915B2 JP6204915B2 (ja) 2017-09-27

Family

ID=47911521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531996A Active JP6204915B2 (ja) 2011-09-23 2012-09-21 悪液質治療

Country Status (16)

Country Link
US (2) US9809649B2 (OSRAM)
EP (1) EP2750709B1 (OSRAM)
JP (1) JP6204915B2 (OSRAM)
KR (1) KR102039198B1 (OSRAM)
CN (1) CN103906536A (OSRAM)
AU (1) AU2012312225B2 (OSRAM)
CA (1) CA2849710C (OSRAM)
DK (1) DK2750709T3 (OSRAM)
ES (1) ES2695102T3 (OSRAM)
IL (1) IL231622B (OSRAM)
MX (1) MX356808B (OSRAM)
PH (1) PH12014500645A1 (OSRAM)
PT (1) PT2750709T (OSRAM)
RU (1) RU2622021C2 (OSRAM)
WO (1) WO2013043973A2 (OSRAM)
ZA (1) ZA201402057B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6324720B2 (ja) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 関節炎治療
KR102748255B1 (ko) 2010-08-23 2024-12-31 엑스바이오테크 인코포레이티드 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP6204915B2 (ja) 2011-09-23 2017-09-27 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 悪液質治療
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US10485502B2 (en) * 2016-12-20 2019-11-26 General Electric Company System and method for assessing muscle function of a patient
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2049342A1 (en) 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0664713B1 (en) 1992-10-14 2000-01-19 Nycomed Imaging As Therapeutic and diagnostic imaging compositions and methods
DK0614984T4 (da) 1993-03-05 2010-12-20 Bayer Healthcare Llc Humane monoklonale anti-TNF-alfa-antistoffer
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
CA2426384A1 (en) 2000-10-19 2003-04-17 Kyowa Hakko Kogyo Co., Ltd. Antibody inhibiting vplf activity
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
PL377091A1 (pl) 2002-09-06 2006-01-23 Amgen, Inc. Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
WO2004100987A2 (en) 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
WO2006062779A2 (en) 2004-12-09 2006-06-15 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
CN109187944A (zh) 2005-08-02 2019-01-11 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
KR20080047564A (ko) 2005-09-28 2008-05-29 사이토스 바이오테크놀로지 아게 인터루킨-1 컨쥬게이트 및 그의 용도
CA2648223A1 (en) 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
AU2007251239B2 (en) 2006-05-15 2013-08-22 Xbiotech Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
PT2109623E (pt) * 2006-05-22 2012-01-12 Xbiotech Inc Tratamento de cancro com anticorpos anti-il-1
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
US8324350B2 (en) 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
JP2011521896A (ja) 2008-04-15 2011-07-28 サーコード コーポレイション 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト
CN105467136B (zh) * 2008-05-30 2018-02-16 埃克斯生物科技公司 白细胞介素‑1α抗体及使用方法
WO2010030979A2 (en) 2008-09-12 2010-03-18 Xbiotech, Inc. Targeting pathogenic monocytes
PE20120586A1 (es) * 2009-01-29 2012-06-17 Abbott Lab Proteinas de union a il-1
TW201124427A (en) 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
JP6324720B2 (ja) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 関節炎治療
KR102748255B1 (ko) 2010-08-23 2024-12-31 엑스바이오테크 인코포레이티드 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
EP2694107B1 (en) 2011-04-01 2018-08-22 XBiotech, Inc Treatment for dermatological pathologies
JP6204915B2 (ja) 2011-09-23 2017-09-27 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 悪液質治療
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CA2886757C (en) 2012-10-04 2022-04-05 Xbiotech Inc. Treatment of anxiety with il1.alpha. antagonist
EP4628162A3 (en) 2012-10-04 2025-12-03 XBiotech Inc. Treating vascular disease and complications thereof

Similar Documents

Publication Publication Date Title
JP2014526559A5 (OSRAM)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
NZ707377A (en) Combination therapy methods for treating proliferative diseases
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
JP2010222367A5 (OSRAM)
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
PH12014500386A1 (en) Combination treatment for hepatitis c
JP2015515475A5 (OSRAM)
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
IN2014DN07149A (OSRAM)
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
RU2014111662A (ru) Лечение кахексии
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
JP2015531396A5 (OSRAM)
BRPI1008103A2 (pt) " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos "
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
UA111480C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ЛІКУВАННЯ СИНДРОМУ ПОДРАЗНЕНОГО КИШЕЧНИКУ, ЯКА ВВОДИТЬСЯ ПЕРОРАЛЬНО, ЩО МІСТИТЬ ТРИМЕБУТИН, СИМЕТИКОН, α-D-ГАЛАКТОЗИДАЗУ, І СПОСІБ ЇЇ ОТРИМАННЯ
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease